Incyte announces validation by EMA of its MAA for pemigatinib in patients with cholangiocarcinoma

This article was originally published here

The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “The EMA’s validation of Incyte’s Marketing

The post Incyte announces validation by EMA of its MAA for pemigatinib in patients with cholangiocarcinoma appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply